MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).

Merck's HIV pill met key efficacy and safety goals in Phase 3 trials, matching Biktarvy as the FDA reviews its application with a 2026 decision date.

Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...

A new pill for sleep apnea could offer hope for those struggling with CPAP machines, according to leading researchers. Trump demands voting changes hours after major Democrat wins CCTV footage shows ...

One of our grandsons is active in the Cub Scout program. His mom, our daughter, has found herself thrust into the role of outdoor activities manager for the den. She asked if I wanted to tag along ...

A Bedford trick-or-treater found a pill in what appeared to be a piece of Halloween candy Wednesday night, according to police.The child had been trick-or-treating on Technology Drive in Bedford ...

Gilead is actively looking for late-stage and de-risked assets for potential deals across various therapeutic spaces, including liver disease, cancer and immunology. Gilead will stay on the lookout ...

“This strategy of [switching to bictegravir/emtricitabine/tenofovir alafenamide] is an appealing one for reducing severe interactions, toxicity and pill burden in ...